<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2026.1760287</article-id>
<article-version article-version-type="Corrected Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of two novel <italic>MVD</italic> mutations and one novel <italic>FDPS</italic> mutation in Chinese patients with porokeratosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Shengcai</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Quan</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Fan</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yunxia</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ouyang</surname>
<given-names>Xiaoliang</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1840775"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Wu</surname>
<given-names>Liang</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0007"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2942044"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Li</surname>
<given-names>Chunming</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<xref ref-type="author-notes" rid="fn0007"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1965208"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Dermatology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University</institution>, <city>Nanchang</city>, <state>Jiangxi</state>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Plastic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University</institution>, <city>Nanchang</city>, <state>Jiangxi</state>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Liang Wu, <email xlink:href="mailto:413007230247@email.ncu.edu.cn">413007230247@email.ncu.edu.cn</email>; Chunming Li, <email xlink:href="mailto:chunminglincu@163.com">chunminglincu@163.com</email></corresp>
<fn fn-type="equal" id="fn0007"><label>&#x2020;</label><p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-29">
<day>29</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="corrected" iso-8601-date="2026-02-09">
<day>09</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>13</volume>
<elocation-id>1760287</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 He, Zhu, Wei, Ye, Zhu, Ouyang, Wu and Li.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>He, Zhu, Wei, Ye, Zhu, Ouyang, Wu and Li</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-29">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Porokeratosis (PK) is an autosomal dominant inherited disorder characterized by abnormal epidermal keratinization, primarily resulting from mutations in four genes associated with the mevalonate pathway: mevalonate decarboxylase (<italic>MVD</italic>), mevalonate kinase (<italic>MVK</italic>), phosphomevalonate kinase (<italic>PMVK</italic>), and farnesyl diphosphate synthase (<italic>FDPS</italic>).</p>
</sec>
<sec>
<title>Purpose</title>
<p>The purpose of this study was to identify the causative mutations in seven sporadic cases of PK.</p>
</sec>
<sec>
<title>Patients and methods</title>
<p>Clinical data and blood samples were collected from these seven sporadic cases. To identify pathogenic gene mutations in the patients, both whole-exome and Sanger sequencing were conducted. Bioinformatics resources such as PROVEAN, SIFT, PolyPhen-2, and Mutation Taster were employed to assess the pathogenicity of the identified mutations.</p>
</sec>
<sec>
<title>Results</title>
<p>This study included seven sporadic cases of PK, comprising two cases of disseminated superficial actinic porokeratosis (DSAP), and five cases of disseminated superficial porokeratosis (DSP). We identified a total of five heterozygous mutations, including two novel <italic>MVD</italic> mutations (c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A, c.576G&#x202F;&#x003E;&#x202F;T), one novel <italic>FDPS</italic> mutation (c.986A&#x202F;&#x003E;&#x202F;C), and two <italic>MVD</italic> mutations that have been reported previously (c.1A&#x202F;&#x003E;&#x202F;G and c.746&#x202F;T&#x202F;&#x003E;&#x202F;C). In conjunction with our previous study, we identified a total of six patients with the <italic>MVD</italic> c.746&#x202F;T&#x202F;&#x003E;&#x202F;C mutation from Jiangxi province, China, representing 50% of the total <italic>MVD</italic> mutation cases (12 in total).</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This research has expanded the database of mevalonate pathway genes associated with PK, thereby improving our comprehension of the fundamental mechanisms involved.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Chinese</kwd>
<kwd>
<italic>FDPS</italic>
</kwd>
<kwd>mutation analysis</kwd>
<kwd>
<italic>MVD</italic>
</kwd>
<kwd>porokeratosis</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was funded by the National Natural Science Foundation of China (Project No. 82460623) and the Natural Science Foundation of Jiangxi Province (No. 20232BAB206126).</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="25"/>
<page-count count="8"/>
<word-count count="4844"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Dermatology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Porokeratosis (PK) is an autosomal dominant inherited disorder characterized by epidermal keratinization. Clinically, it presents as one or more annular skin lesions, which exhibit central atrophy and depression, accompanied by a keratinized border. Histopathologically, it is defined by the presence of a keratin-like layer (<xref ref-type="bibr" rid="ref1">1</xref>). According to clinical features, PK can be classified into six relatively prevalent subtypes: disseminated superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis (DSP), porokeratosis of Mibelli (PM), punctate porokeratosis (PP), porokeratosis palmaris et plantaris disseminata (PPPD), and linear porokeratosis (LP) (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>). PK is recognized as a genetically heterogeneous disorder, primarily resulting from mutations in one of four mevalonate pathway genes: <italic>MVK</italic>, <italic>MVD</italic>, <italic>FDPS</italic> and <italic>PMVK</italic> (<xref ref-type="bibr" rid="ref3">3</xref>). Additionally, mutations in the <italic>SLC17A9</italic>, <italic>FDFT1</italic>, <italic>SSH1</italic>, and <italic>SART3</italic> genes may also be implicated as causative factors in PK (<xref ref-type="bibr" rid="ref4 ref5 ref6 ref7">4&#x2013;7</xref>).</p>
<p>In our earlier research, we discovered a new mutation in <italic>MVD</italic> (c.683G&#x202F;&#x003E;&#x202F;C), a new <italic>FDPS</italic> mutation (c.438&#x202F;T&#x202F;&#x003E;&#x202F;G), along with three previously documented <italic>MVD</italic> mutations (c.1111_1113del, c.875A&#x202F;&#x003E;&#x202F;G, and c.746&#x202F;T&#x202F;&#x003E;&#x202F;C) among PK cases from Jiangxi province in China (<xref ref-type="bibr" rid="ref8">8</xref>). To gain deeper insight into the mutation spectrum associated with PK, we conducted a mutation analysis on genes in seven sporadic PK cases.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Patients recruitment and sample collection</title>
<p>This study included seven sporadic cases of PK from Jiangxi province in China. Clinical data, along with around 5&#x202F;mL of peripheral blood, were gathered from participants who signed informed consent. All the clinical diagnosis based on the manifestations and histopathological examinations. This study was approved by the Clinical Research Ethics Committee of the Second Affiliated Hospital of Nanchang University.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>DNA extraction and whole-exome sequencing (WES)</title>
<p>Genomic DNA was extracted from peripheral blood samples using the Puregene Blood Core Kit B (QIAGEN, Hilden, Germany) in accordance with standard protocols. WES was carried out based on previously outlined methods (<xref ref-type="bibr" rid="ref9">9</xref>). For each individual, 1.5&#x202F;&#x03BC;g of genomic DNA was employed to create a captured library, which was later sequenced on the HiSeq X 10 platform (Illumina, San Diego, USA), yielding 150&#x202F;bp paired-end reads. The raw data, totaling approximately 10&#x202F;GB per exome, were aligned to the human reference genome sequence (GRCh38/hg38) employing the Burrows-Wheeler Alignment (BWA) tool.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Variant calling and gene filtration</title>
<p>In our study, we performed variant calling using the Genome Analysis Toolkit (GATK). Subsequently, we utilized ANNOVAR software for the comprehensive annotation of all identified variants. Our research specifically focused on identifying novel and rare protein-altering variants, which included various types of mutations such as frameshift, missense, nonsense, and critical splicing-site variations. We analyzed the frequency of these variants across different ethnic subgroups, leveraging data sourced from reputable genomic databases, including the 1,000 Genomes Project, the Exome Aggregation Consortium (ExAC), and the Genome Aggregation Database (gnomAD). Our primary focus was on alterations occurring within coding sequences, also known as exonic variants. Additionally, we investigated certain noncoding sequence variants located at the boundaries of exons and introns, which either had an unknown frequency or exhibited a minor allele frequency of less than 1%, as documented in the aforementioned databases.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Sanger sequencing</title>
<p>The design of primer pairs was accomplished using Primer 5.0 software to amplify the exons along with their respective exon/intron boundaries. The appropriate primers used for PCR amplifications included: <italic>MVD</italic> c.746&#x202F;T&#x202F;&#x003E;&#x202F;C (Forward Primer: TGTAAAACGACGGCCAGTAGGAGATGGCAT TGAGGTAAGAGATG; Reverse Primer: CAGGAAACAGCTATGACCGCAGGAGCCAAATG CAGAGAT), <italic>MVD</italic> c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A (Forward Primer: TGTAAAACGACGGCCAGTCAAATGAATGGACAAAGGCGTTCT; Reverse Primer: CAGGAAACAGCTATGACCGCTTAGAGAAACGGATGCATTCAC), and <italic>FDPS</italic> c.986A&#x202F;&#x003E;&#x202F;C (Forward Primer: CAGAGAACAGGCACCAG CTTCA; Reverse Primer: GCTCTATCCCTTTCCACCAACTCA). Details of the PCR conditions can be provided upon request. The purification of PCR products was carried out utilizing SAP (Promega, Madison, WI, USA) in combination with Exo I (Epicentre, Madison, WI, USA). Sequencing of the purified PCR products was performed with the dye terminator chemistry BigDye3.1 (Applied Biosystems, Foster City, CA, USA). The sequencing reactions were analyzed on a 3730xl genetic analyzer from Applied Biosystems. For comparisons and analysis of the sequences, PolyPhred Analysis Software was employed.</p>
</sec>
</sec>
<sec sec-type="results" id="sec7">
<label>3</label>
<title>Results</title>
<sec id="sec8">
<label>3.1</label>
<title>Clinical manifestations</title>
<p>This study comprised a total of seven sporadic cases of PK (<xref ref-type="table" rid="tab1">Table 1</xref>). The first case involved a 62-year-old male who began to notice the development of multiple keratotic papules on his face, trunk, and limbs at the age of 52, as depicted in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. The second case highlighted a 55-year-old male who exhibited typical keratotic papules on the trunk, arms, and legs since the age of 50, illustrated in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. In the third case, a 54-year-old female presented with numerous keratotic lesions primarily located on areas of her body that were frequently exposed to the sun. These lesions had been persistent for 7&#x202F;years, demonstrating a tendency to worsen during the summer months while showing signs of involution during the wintertime, as shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. This patient had previously attempted to treat her condition with tretinoin ointment, though unfortunately, her symptoms did not improve. The fourth sporadic case featured a 52-year-old female who had been experiencing multiple small hyperkeratotic plaques for over a decade, as depicted in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. The fifth case involved a 63-year-old female who developed multiple rounded hyperkeratotic plaques that displayed central atrophy and peripheral ridging, as illustrated in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. The sixth case was a 70-year-old female who displayed a manifestation mirroring that of the third sporadic case, highlighted in <xref ref-type="fig" rid="fig1">Figure 1F</xref>. Lastly, the seventh case presented a 68-year-old male who developed small, scattered dark brown patches across his trunk, arms, and legs over a period of 6&#x202F;months, as shown in <xref ref-type="fig" rid="fig1">Figure 1G</xref>. Sporadic cases 1, 2, 4, 5, and 7 were diagnosed with DSP, while sporadic cases 3 and 6 were diagnosed with DSAP.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Summary of the clinical manifestations and mutations of 7 patients with PK.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" char="&#x00D7;" rowspan="2">Patient</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Phenotype</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Gender/age</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Age at onset</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Place of residence</th>
<th align="char" valign="top" char="&#x00D7;" colspan="3">Affected skin lesions</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Gene</th>
<th align="char" valign="top" char="&#x00D7;" rowspan="2">Mutation</th>
</tr>
<tr>
<th align="char" valign="top" char="&#x00D7;">Face-neck</th>
<th align="char" valign="top" char="&#x00D7;">Trunk</th>
<th align="char" valign="top" char="&#x00D7;">Limbs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case 1</td>
<td align="left" valign="middle">DSP</td>
<td align="left" valign="middle">Male/62&#x202F;y</td>
<td align="center" valign="middle">52&#x202F;y</td>
<td align="left" valign="middle">Nanchang city</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.746&#x202F;T&#x202F;&#x003E;&#x202F;C</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case2</td>
<td align="left" valign="middle">DSP</td>
<td align="left" valign="middle">Male/55&#x202F;y</td>
<td align="center" valign="middle">50&#x202F;y</td>
<td align="left" valign="middle">Fengcheng city</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case3</td>
<td align="left" valign="middle">DSAP</td>
<td align="left" valign="middle">Female/54&#x202F;y</td>
<td align="center" valign="middle">47&#x202F;y</td>
<td align="left" valign="middle">Nanchang city</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.746&#x202F;T&#x202F;&#x003E;&#x202F;C</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case4</td>
<td align="left" valign="middle">DSP</td>
<td align="left" valign="middle">Female/52&#x202F;y</td>
<td align="center" valign="middle">40&#x202F;y</td>
<td align="left" valign="middle">Yongfeng country</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>FDPS</italic></td>
<td align="center" valign="middle">c.986A&#x202F;&#x003E;&#x202F;C</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case5</td>
<td align="left" valign="middle">DSP</td>
<td align="left" valign="middle">Female/63&#x202F;y</td>
<td align="center" valign="middle">46&#x202F;y</td>
<td align="left" valign="middle">Nanchang city</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.1A&#x202F;&#x003E;&#x202F;G</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case6</td>
<td align="left" valign="middle">DSAP</td>
<td align="left" valign="middle">Female/70&#x202F;y</td>
<td align="center" valign="middle">67&#x202F;y</td>
<td align="left" valign="middle">Nanchang city</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.746&#x202F;T&#x202F;&#x003E;&#x202F;C</td>
</tr>
<tr>
<td align="left" valign="middle" char="&#x00D7;">Sporadic case7</td>
<td align="left" valign="middle">DSP</td>
<td align="left" valign="middle">Male/68&#x202F;y</td>
<td align="center" valign="middle">67&#x202F;y</td>
<td align="left" valign="middle">Xingguo country</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle"><italic>MVD</italic></td>
<td align="center" valign="middle">c.576G&#x202F;&#x003E;&#x202F;T</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>DSP, disseminated superficial porokeratosis; DSAP, disseminated superficial actinic porokeratosis.</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Clinical manifestations of seven sporadic cases of PK. <bold>(A)</bold> Sporadic case 1 (DSP); <bold>(B)</bold> Sporadic case 2 (DSP); <bold>(C)</bold> Sporadic case 3 (DSAP); <bold>(D)</bold> Sporadic case 4 (DSP); <bold>(E)</bold> Sporadic case 5 (DSP); <bold>(F)</bold> Sporadic case 6 (DSAP); <bold>(G)</bold> Sporadic case 7 (DSP).</p>
</caption>
<graphic xlink:href="fmed-13-1760287-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Images labeled A to G show various parts of a person's body with multiple brown spots and lesions. A: Side view of the neck. B: Front view of the chest and neck. C: Close-up of the cheek. D: Forearm with reddish-brown spots. E: Side profile of the face with lesions. F: Forearm with numerous spots. G: Close-up of the neck area.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec9">
<label>3.2</label>
<title>Mutation analysis</title>
<p>Three novel mutations were identified among seven sporadic patients (<xref ref-type="table" rid="tab1">Table 1</xref>). The novel mutation <italic>MVD</italic> c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A was identified in sporadic case 2 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The novel mutation <italic>FDPS</italic> c.986A&#x202F;&#x003E;&#x202F;C (p. Q329P) was detected in sporadic case 4; this missense mutation resulted in the substitution of glutamine with proline at codon 329 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Additionally, the novel mutation <italic>MVD</italic> c.576G&#x202F;&#x003E;&#x202F;T (p. W192C) was identified in sporadic case 7, leading to a substitution of tryptophan with cysteine at codon 192 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Furthermore, the recurrent <italic>MVD</italic> mutation c.746&#x202F;T&#x202F;&#x003E;&#x202F;C (p. F249S) was observed in sporadic cases 1, 3, and 6. Another recurrent <italic>MVD</italic> mutation, c.1A&#x202F;&#x003E;&#x202F;G (p. M1V), was found in sporadic case 5.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Genetic mutation of mevalonate pathway genes in this study. <bold>(A)</bold> A novel mutation <italic>MVD</italic> c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A was found in sporadic case 2. <bold>(B)</bold> A novel mutation <italic>FDPS</italic> c.986A&#x202F;&#x003E;&#x202F;C (p. Q329P) was detected in sporadic case 4. <bold>(C)</bold> A novel mutation <italic>MVD</italic> c.576G&#x202F;&#x003E;&#x202F;T (p. W192C) was identified in sporadic case 7. The black arrow indicates the mutation site.</p>
</caption>
<graphic xlink:href="fmed-13-1760287-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three panels of DNA sequencing chromatograms, labeled A, B, and C. A shows MVD c.1122+1G&#x003E;A with a mutation at the G nucleotide. B displays FDPS c.986A&#x003E;C with a mutation at the A nucleotide. C presents MVD c.576G&#x003E;T with a mutation at the G nucleotide. Arrows indicate mutation locations.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec10">
<label>3.3</label>
<title>Bioinformatics analysis of the mutation</title>
<p>The UCSC Genome Browser<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> was utilized to investigate the evolutionary conservation of amino acids that have undergone mutations. An alignment of multiple sequences of homologous proteins from humans and various other vertebrates revealed that <italic>FDPS</italic> c.986A&#x202F;&#x003E;&#x202F;C and <italic>MVD</italic> c.576G&#x202F;&#x003E;&#x202F;T mutation occurred at highly conserved sites (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Conservation of amino acid sequences in the corresponding mutation of <italic>FDPS</italic> and <italic>MVD</italic> between species. The black arrow represents the amino acid at the mutated site. <bold>(A)</bold> c.986A&#x202F;&#x003E;&#x202F;C (p. Q329P) mutation in <italic>FDPS</italic>. <bold>(B)</bold> c.576G&#x202F;&#x003E;&#x202F;T(p. W192C) mutations in <italic>MVD</italic>.</p>
</caption>
<graphic xlink:href="fmed-13-1760287-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Two panels (A and B) displaying sequence alignments of vertebrate conservation using PhyloP scores. Panel A illustrates the FDPS gene mutation c.986A&#x003E;C causing p.Q329P substitution with a nucleotide sequence and alignment across different species including human, mouse, and zebrafish. Panel B shows the MVD gene mutation c.576G&#x003E;T causing p.W192C substitution with corresponding sequence conservation. Arrows indicate specific positions of the mutations within the alignments.</alt-text>
</graphic>
</fig>
<p>To further explore the molecular structures of the wild type (WT) and mutant proteins, we constructed three-dimensional computer models using the I-TASSER server.<xref ref-type="fn" rid="fn0002"><sup>2</sup></xref> As illustrated in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, the WT protein contains a polar glutamine residue at position 329, which forms stable hydrogen bonds with three neighboring residues: GLY325, THR326, and LYS359. In contrast, the p. GLN329PRO mutation substitutes GLN329 with a non-polar proline, thereby abolishing the hydrogen bonds with GLY325 and THR326. As depicted in <xref ref-type="fig" rid="fig4">Figure 4B</xref>, the WT protein features a non-polar tryptophan at position 192 that forms a hydrogen bond with the adjacent leucine (LEU195). Furthermore, the aromatic indole ring of TRP192 engages in <italic>&#x03C0;</italic>-&#x03C0; stacking with the benzene ring of phenylalanine (PHE252) and forms &#x03C0;-alkyl interactions with the side chains of arginine (ARG247) and LEU195. In the p. TRP192CYS mutant protein, the side chain of cysteine (CYS192) engages in weak alkyl interactions with ARG247 and LEU195, resulting in the complete abrogation of the hydrogen bond formed by WT TRP192.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Three-dimensional structure of wild-type (WT) proteins and the novel mutant proteins. <bold>(A)</bold> The p. GLN329PRO mutation substitutes GLN329 with a non-polar proline, thereby abolishing the hydrogen bonds with GLY325 and THR326. <bold>(B)</bold> In the p. TRP192CYS mutant protein, the side chain of cysteine (CYS192) engages in weak alkyl interactions with ARG247 and LEU195, resulting in the complete abrogation of the hydrogen bond formed by WT TRP192.</p>
</caption>
<graphic xlink:href="fmed-13-1760287-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Two panels labeled A and B show protein structures with detailed views of interactions. Panel A features a protein with colored helices, highlighting GLN-329 and PRO-329 interactions with residues GLY-325, THR-326, and LYS-359, with distances marked in angstroms. Panel B shows another protein structure, highlighting TRP-192 and CYS-192 interactions with PHE-252, ARG-247, and LEU-195, with similar distance annotations.</alt-text>
</graphic>
</fig>
<p>To assess the potential pathogenicity, four online tools were utilized: PROVEAN<xref ref-type="fn" rid="fn0003"><sup>3</sup></xref> (<xref ref-type="bibr" rid="ref10">10</xref>), PolyPhen-2<xref ref-type="fn" rid="fn0004"><sup>4</sup></xref> (<xref ref-type="bibr" rid="ref11">11</xref>), SIFT<xref ref-type="fn" rid="fn0005"><sup>5</sup></xref> (<xref ref-type="bibr" rid="ref12">12</xref>), and Mutation Taster<xref ref-type="fn" rid="fn0006"><sup>6</sup></xref> (<xref ref-type="bibr" rid="ref13">13</xref>). The novel <italic>FDPS</italic> mutation c.986A&#x202F;&#x003E;&#x202F;C was classified as &#x201C;deleterious&#x201D; with a score of &#x2212;4.78 by PROVEAN, &#x201C;probably damaging&#x201D; with a score of 1.000 by PolyPhen2, &#x201C;Damaging&#x201D; with a score of 0.00 by SIFT, and labeled &#x201C;disease-causing&#x201D; with a probability of 0.999 by Mutation Taster. Similarly, the other novel <italic>MVD</italic> mutation c.576G&#x202F;&#x003E;&#x202F;T was characterized as &#x201C;deleterious&#x201D; with a score of &#x2212;12.78 by PROVEAN, &#x201C;probably damaging&#x201D; with a score of 1.000 by PolyPhen2, &#x201C;Damaging&#x201D; with a score of 0.00 by SIFT, and recognized as &#x201C;disease-causing&#x201D; with a probability of 0.999 by Mutation Taster. Furthermore, the splice site mutation c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A was analyzed using the RNA splicer algorithms provided by the Rare Disease Data Center (RDDC). The results suggest that this specific mutation may lead to a change in the reading frame, skipping of exon 9, and deletion of a 109&#x202F;bp fragment, resulting in a frameshift mutation (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Prediction results of RDDC RNA splicer algorithms: the splice site mutation <italic>MVD</italic> c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A may lead to a change in the reading frame, exon skipping of exon 9, and deletion of a 109&#x202F;bp fragment, causing a frameshift mutation.</p>
</caption>
<graphic xlink:href="fmed-13-1760287-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Genetic diagram illustrating a splice pattern for MVD gene location chr16:88653299 (hg38), NM_002461.3, c.1122+1C&#x003E;T. It shows deletion of 109 base pairs, exon skipping, and a frameshift mutation with a specific mutation of guanine to adenine marked between exons E9 and E10.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec11">
<label>3.4</label>
<title>Review of <italic>MVD</italic> mutation c.746&#x202F;T&#x202F;&#x003E;&#x202F;C in Jiangxi Province</title>
<p>In our earlier research, Wang et al. reported six patients with <italic>MVD</italic> mutations, three of whom had the c.746&#x202F;T&#x202F;&#x003E;&#x202F;C mutation (<xref ref-type="bibr" rid="ref8">8</xref>). In conjunction with this study, we identified a total of six patients with the <italic>MVD</italic> c.746&#x202F;T&#x202F;&#x003E;&#x202F;C mutation from Jiangxi province, China, representing 50% of the total <italic>MVD</italic> mutation cases (12 in total). These patients are all sporadic cases, comprnsisting of four males and two females, with an age of onset ranging from 3 to 67&#x202F;years. All these individuals hail from the northern part of Jiangxi Province in China, and there is no evidence of familial connections among them in recent generational lines. They include two cases of DSAP, three cases of DSP, and one case of LP.</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec12">
<label>4</label>
<title>Discussion</title>
<p>In Zhang et al. (<xref ref-type="bibr" rid="ref14">14</xref>) conducted a study utilizing exome sequencing on individuals diagnosed with DSAP, which led to the identification of mutations in the <italic>MVK</italic> gene. In 2015, it was confirmed that mutations in genes encoding three other mevalonate pathway genes (<italic>MVD, FDPS</italic>, and <italic>PMVK</italic>) also contributed to the occurrence of DSAP and various other PK subtypes (<xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref15">15</xref>, <xref ref-type="bibr" rid="ref16">16</xref>). In our study, we identified two novel <italic>MVD</italic> mutations and one novel <italic>FDPS</italic> mutation in cases of PK from Jiangxi province, China.</p>
<p>The <italic>MVD</italic> gene, situated in the 16q24.1&#x2013;24.3 locus, comprises 10 exons and encodes Mevalonate 5-diphosphate decarboxylase. This enzyme facilitates the decarboxylation of mevalonate 5-diphosphate in an ATP-dependent manner, resulting in the production of isopentenyl diphosphate, which is a vital precursor for dolichol, cholesterol, ubiquinones, isoprenylated protein, and sheme A. In our study, the novel mutation <italic>MVD</italic> c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A was found in sporadic case 2. According to predictions made by the RNA Splicer tool, this particular mutation disrupts the normal splicing process by leading to the exclusion of exon 9. The skipping of this exon results in a frameshift mutation, which in turn triggers alternative splicing and consequently has a significant impact on the coding sequence of the protein. Hence, we hypothesize that this mutated protein is probably nonfunctional, contributing to disease pathogenesis. Additionally, the <italic>MVD</italic> mutation c.576G&#x202F;&#x003E;&#x202F;T, observed in sporadic case 7, is categorized as a missense mutation. The protein structure prediction model suggests that the p. GLN329PRO mutation replaces GLN329 with PRO, which removes the hydrogen bonds with GLY325 and THR326. We speculate that these alterations induce conformational changes and functional impairments in the protein, leading to the onset of PK.</p>
<p>The <italic>FDPS</italic> gene, found at chromosome 1q22, consists of 10 exons and encodes the enzyme Farnesyl diphosphate synthase (<xref ref-type="bibr" rid="ref17">17</xref>). This enzyme catalyzes the conversion of isopentenyl pyrophosphate and dimethylallyl pyrophosphate into geranyl pyrophosphate and farnesyl pyrophosphate (<xref ref-type="bibr" rid="ref18">18</xref>). Farnesyl diphosphate, the ultimate product of this enzymatic process, is essential for cholesterol synthesis and acts as a ligand or agonist in interactions with specific hormones and proteins. In our study, a novel <italic>FDPS</italic> mutation, c.986A&#x202F;&#x003E;&#x202F;C, was found in sporadic case 4. Protein structure modeling indicates that in the p. Trp192Cys mutant protein, the side chain of Cys192 engages in weak alkyl interactions with Arg247 and Leu195, resulting in the complete abrogation of the hydrogen bond formed by wild-type Trp192, leading to functional loss of the protein. To date, only 10 mutations (c.1129_141&#x202F;+&#x202F;994del, c.283&#x2013;1776_649&#x2013;143del, c.200&#x202F;T&#x202F;&#x003E;&#x202F;C, c.338G&#x202F;&#x003E;&#x202F;A, c.438&#x202F;T&#x202F;&#x003E;&#x202F;G, c.486&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A, c.535C&#x202F;&#x003E;&#x202F;T, c.634_635delTA, c.773&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A, and c.1163_1164insA) in the <italic>FDPS</italic> gene have been reported in patients with PK (<xref ref-type="bibr" rid="ref3">3</xref>, <xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref19 ref20 ref21 ref22">19&#x2013;22</xref>). It has been noted that the skin lesions present in PK patients with <italic>FDPS</italic> mutations display a homogeneous and superficial nature (<xref ref-type="bibr" rid="ref19">19</xref>). The lesions observed in sporadic case 4 are consistent with this characteristic.</p>
<p>The mutation <italic>MVD</italic> c.746&#x202F;T&#x202F;&#x003E;&#x202F;C has been reported as a hot-spot mutation (<xref ref-type="bibr" rid="ref3">3</xref>). In our study, the <italic>MVD</italic> mutation c.746&#x202F;T&#x202F;&#x003E;&#x202F;C was observed in sporadic cases 1, 3, and 7. In conjunction with our previous study, we identified a total of six patients with the <italic>MVD</italic> c.746&#x202F;T&#x202F;&#x003E;&#x202F;C mutation from Jiangxi province, China, representing 50% of the total <italic>MVD</italic> mutation cases. Similarly, Leng et al. observed that this mutation was found in three families, constituting 50% all patients with <italic>MVD</italic> mutations in their cohort (<xref ref-type="bibr" rid="ref23">23</xref>). Furthermore, despite carrying the same mutation, the age of onset and clinical subtype varied among patients. This variability may be associated with the development of PK, influenced by factors such as ultraviolet exposure, genetic susceptibility, immunosuppression, radiation, medications, and viral infections.</p>
<p>Genetic insights into the pathogenesis of PK provide guidance for therapies directed at specific pathophysiological mechanisms. The mevalonate pathway produces various end products that are critical for numerous cellular functions, including cholesterol, geranylgeranyl pyrophosphate, ubiquinone, dolichol, isopentenyladenine, and farnesyl pyrophosphate. Dysregulation of the mevalonate pathway decreases the production of these end products, leading to the accumulation of toxic metabolites. Future therapeutic directions should focus on correcting the metabolic anomalies resulting from the disordered mevalonate pathway. A novel topical treatment targeting the HMG-CoA reductase enzyme, utilizing 2% lovastatin, along with the replacement of cholesterol as an end product of the cholesterol synthesis pathway (2% cholesterol), has been described in the treatment of PK (<xref ref-type="bibr" rid="ref24">24</xref>). A recent study indicated that both lovastatin 2% plus cholesterol 2% and lovastatin 2% alone equally improved lesions of DSAP over the study period, suggesting that cholesterol may not be necessary in formulations and that lovastatin cream may serve as a new primary treatment option for patients diagnosed with DSAP (<xref ref-type="bibr" rid="ref25">25</xref>). However, there is currently a lack of therapeutic studies targeting other end products of the mevalonate pathway. Therefore, further research in this area will help provide new therapeutic directions for the treatment of PK.</p>
<p>This study has several limitations. Firstly, the analysis of the pathogenic mechanisms of novel gene variants primarily relies on bioinformatics analyses. Such bioinformatics-based predictive analyses can only infer potential pathogenic mechanisms based on the impact of a variant on protein structure. Therefore, functional experiments for further validation are necessary. Additionally, the number of patients analyzed was relatively small.</p>
</sec>
<sec sec-type="conclusions" id="sec13">
<label>5</label>
<title>Conclusion</title>
<p>In conclusion, we identified two novel <italic>MVD</italic> mutations (c.1122&#x202F;+&#x202F;1G&#x202F;&#x003E;&#x202F;A, c.576G&#x202F;&#x003E;&#x202F;T), and one novel <italic>FDPS</italic> mutation (c.986A&#x202F;&#x003E;&#x202F;C). This research has expanded the database of mevalonate pathway genes associated with PK, thereby improving our comprehension of the fundamental mechanisms involved. Further studies will focus on functional studies to elucidate the molecular mechanisms underlying PK pathogenesis.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec14">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository and accession number(s) can be found below: NCBI GenBank; PX769337, PX769338 and PX769339.</p>
</sec>
<sec sec-type="ethics-statement" id="sec15">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Clinical Research Ethics Committee of the Second Affiliated Hospital of Nanchang University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="sec16">
<title>Author contributions</title>
<p>YH: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Data curation, Formal analysis, Investigation, Methodology, Visualization. SZ: Data curation, Visualization, Writing &#x2013; review &#x0026; editing. QW: Data curation, Writing &#x2013; review &#x0026; editing, Formal analysis. FY: Data curation, Formal analysis, Writing &#x2013; review &#x0026; editing. YZ: Formal analysis, Writing &#x2013; review &#x0026; editing. XO: Formal analysis, Writing &#x2013; review &#x0026; editing. LW: Formal analysis, Supervision, Visualization, Writing &#x2013; review &#x0026; editing. CL: Writing &#x2013; review &#x0026; editing, Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; original draft.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank all patients for participating in this study.</p>
</ack>
<sec sec-type="COI-statement" id="sec17">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="correction-note" id="sec018">
<title>Correction note</title>
<p>A correction has been made to this article. Details can be found at: <ext-link xlink:href="https://doi.org/10.3389/fmed.2026.1799246" ext-link-type="uri">10.3389/fmed.2026.1799246</ext-link>.</p>
</sec>
<sec sec-type="ai-statement" id="sec18">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec19">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sertznig</surname><given-names>P</given-names></name> <name><surname>von Felbert</surname><given-names>V</given-names></name> <name><surname>Megahed</surname><given-names>M</given-names></name></person-group>. <article-title>Porokeratosis: present concepts</article-title>. <source>J Eur Acad Dermatol Venereol</source>. (<year>2012</year>) <volume>26</volume>:<fpage>404</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1468-3083.2011.04275.x</pub-id>, <pub-id pub-id-type="pmid">21929548</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>T</given-names></name> <name><surname>Ansari</surname><given-names>MH</given-names></name></person-group>. <article-title>A case of linear Porokeratosis</article-title>. <source>Indian Dermatol Online J</source>. (<year>2023</year>) <volume>14</volume>:<fpage>552</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.4103/idoj.idoj_408_22</pub-id>, <pub-id pub-id-type="pmid">37521240</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name> <name><surname>Li</surname><given-names>C</given-names></name> <name><surname>Wu</surname><given-names>F</given-names></name> <name><surname>Ma</surname><given-names>R</given-names></name> <name><surname>Luan</surname><given-names>J</given-names></name> <name><surname>Yang</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Genomic variations of the mevalonate pathway in porokeratosis</article-title>. <source>eLife</source>. (<year>2015</year>) <volume>4</volume>:<fpage>e06322</fpage>. doi: <pub-id pub-id-type="doi">10.7554/eLife.06322</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name> <name><surname>Li</surname><given-names>L</given-names></name> <name><surname>Wang</surname><given-names>W</given-names></name> <name><surname>Shen</surname><given-names>J</given-names></name> <name><surname>Yue</surname><given-names>Z</given-names></name> <name><surname>Zheng</surname><given-names>X</given-names></name> <etal/></person-group>. <article-title>Exome sequencing identifies SLC17A9 pathogenic gene in two Chinese pedigrees with disseminated superficial actinic porokeratosis</article-title>. <source>J Med Genet</source>. (<year>2014</year>) <volume>51</volume>:<fpage>699</fpage>&#x2013;<lpage>704</lpage>.</mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S</given-names></name> <name><surname>Saito</surname><given-names>Y</given-names></name> <name><surname>Sato</surname><given-names>S</given-names></name> <name><surname>Aoki</surname><given-names>S</given-names></name> <name><surname>Fujita</surname><given-names>H</given-names></name> <name><surname>Ito</surname><given-names>Y</given-names></name> <etal/></person-group>. <article-title>Gene-specific somatic epigenetic mosaicism of FDFT1 underlies a non-hereditary localized form of porokeratosis</article-title>. <source>Am J Hum Genet</source>. (<year>2024</year>) <volume>111</volume>:<fpage>896</fpage>&#x2013;<lpage>912</lpage>.</mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name> <name><surname>Niu</surname><given-names>Z</given-names></name> <name><surname>Yuan</surname><given-names>W</given-names></name> <name><surname>Liu</surname><given-names>W</given-names></name> <name><surname>Xiang</surname><given-names>L</given-names></name> <name><surname>Zhang</surname><given-names>J</given-names></name> <etal/></person-group>. <article-title>Fine mapping and identification of a candidate gene SSH1 in disseminated superficial actinic porokeratosis</article-title>. <source>Hum Mutat</source>. (<year>2004</year>) <volume>24</volume>:<fpage>438</fpage>.</mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZH</given-names></name> <name><surname>Niu</surname><given-names>ZM</given-names></name> <name><surname>Yuan</surname><given-names>WT</given-names></name> <name><surname>Zhao</surname><given-names>JJ</given-names></name> <name><surname>Jiang</surname><given-names>FX</given-names></name> <name><surname>Zhang</surname><given-names>J</given-names></name> <etal/></person-group>. <article-title>A mutation in SART3 gene in a Chinese pedigree with disseminated superficial actinic porokeratosis</article-title>. <source>Br J Dermatol</source>. (<year>2005</year>) <volume>152</volume>:<fpage>658</fpage>&#x2013;<lpage>63</lpage>.</mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name> <name><surname>Ouyang</surname><given-names>X</given-names></name> <name><surname>Zhang</surname><given-names>D</given-names></name> <name><surname>Zhu</surname><given-names>Y</given-names></name> <name><surname>Wu</surname><given-names>L</given-names></name> <name><surname>Xiao</surname><given-names>Z</given-names></name> <etal/></person-group>. <article-title>Two novel and three recurrent mutations in the mevalonate pathway genes in Chinese patients with porokeratosis</article-title>. <source>Clin Cosmet Investig Dermatol</source>. (<year>2024</year>) <volume>17</volume>:<fpage>191</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.2147/CCID.S444985</pub-id>, <pub-id pub-id-type="pmid">38283795</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name> <name><surname>Zhang</surname><given-names>D</given-names></name> <name><surname>Wu</surname><given-names>L</given-names></name> <name><surname>Ouyang</surname><given-names>X</given-names></name> <name><surname>Zhu</surname><given-names>S</given-names></name> <name><surname>Wang</surname><given-names>X</given-names></name> <etal/></person-group>. <article-title>Two novel and two recurrent variants of the ADAR1 gene in three Chinese families with Dyschromatosis Symmetrica Hereditaria</article-title>. <source>Clin Cosmet Investig Dermatol</source>. (<year>2024</year>) <volume>17</volume>:<fpage>2373</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.2147/CCID.S477138</pub-id>, <pub-id pub-id-type="pmid">39469661</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y</given-names></name> <name><surname>Sims</surname><given-names>GE</given-names></name> <name><surname>Murphy</surname><given-names>S</given-names></name> <name><surname>Miller</surname><given-names>JR</given-names></name> <name><surname>Chan</surname><given-names>AP</given-names></name></person-group>. <article-title>Predicting the functional effect of amino acid substitutions and indels</article-title>. <source>PLoS One</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e46688</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0046688</pub-id>, <pub-id pub-id-type="pmid">23056405</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name> <name><surname>Schmidt</surname><given-names>S</given-names></name> <name><surname>Peshkin</surname><given-names>L</given-names></name> <name><surname>Ramensky</surname><given-names>VE</given-names></name> <name><surname>Gerasimova</surname><given-names>A</given-names></name> <name><surname>Bork</surname><given-names>P</given-names></name> <etal/></person-group>. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source>Nat Methods</source>. (<year>2010</year>) <volume>7</volume>:<fpage>248</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaser</surname><given-names>R</given-names></name> <name><surname>Adusumalli</surname><given-names>S</given-names></name> <name><surname>Leng</surname><given-names>SN</given-names></name> <name><surname>Sikic</surname><given-names>M</given-names></name> <name><surname>Ng</surname><given-names>PC</given-names></name></person-group>. <article-title>SIFT missense predictions for genomes</article-title>. <source>Nat Protoc</source>. (<year>2016</year>) <volume>11</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>JM</given-names></name> <name><surname>Cooper</surname><given-names>DN</given-names></name> <name><surname>Schuelke</surname><given-names>M</given-names></name> <name><surname>Seelow</surname><given-names>D</given-names></name></person-group>. <article-title>MutationTaster2: mutation prediction for the deep-sequencing age</article-title>. <source>Nat Methods</source>. (<year>2014</year>) <volume>11</volume>:<fpage>361</fpage>&#x2013;<lpage>2</lpage>.</mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SQ</given-names></name> <name><surname>Jiang</surname><given-names>T</given-names></name> <name><surname>Li</surname><given-names>M</given-names></name> <name><surname>Zhang</surname><given-names>X</given-names></name> <name><surname>Ren</surname><given-names>YQ</given-names></name> <name><surname>Wei</surname><given-names>SC</given-names></name> <etal/></person-group>. <article-title>Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis</article-title>. <source>Nat Genet</source>. (<year>2012</year>) <volume>44</volume>:<fpage>1156</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name> <name><surname>Wu</surname><given-names>J</given-names></name> <name><surname>Tang</surname><given-names>H</given-names></name> <name><surname>Zhen</surname><given-names>Q</given-names></name> <name><surname>Ge</surname><given-names>H</given-names></name> <name><surname>Gao</surname><given-names>J</given-names></name> <etal/></person-group>. <article-title>Mutation analysis of the MVD gene in a Chinese family with disseminated superficial actinic Porokeratosis and a Chinese literature review</article-title>. <source>Indian J Dermatol</source>. (<year>2021</year>) <volume>66</volume>:<fpage>126</fpage>&#x2013;<lpage>31</lpage>.</mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atzmony</surname><given-names>L</given-names></name> <name><surname>Khan</surname><given-names>HM</given-names></name> <name><surname>Lim</surname><given-names>YH</given-names></name> <name><surname>Paller</surname><given-names>AS</given-names></name> <name><surname>Levinsohn</surname><given-names>JL</given-names></name> <name><surname>Holland</surname><given-names>KE</given-names></name> <etal/></person-group>. <article-title>Second-hit, postzygotic PMVK and MVD mutations in linear Porokeratosis</article-title>. <source>JAMA Dermatol</source>. (<year>2019</year>) <volume>155</volume>:<fpage>548</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2019.0016</pub-id>, <pub-id pub-id-type="pmid">30942823</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastar</surname><given-names>I</given-names></name> <name><surname>Stojadinovic</surname><given-names>O</given-names></name> <name><surname>Sawaya</surname><given-names>AP</given-names></name> <name><surname>Stone</surname><given-names>RC</given-names></name> <name><surname>Lindley</surname><given-names>LE</given-names></name> <name><surname>Ojeh</surname><given-names>N</given-names></name> <etal/></person-group>. <article-title>Skin metabolite, farnesyl pyrophosphate, regulates epidermal response to inflammation, oxidative stress, and migration</article-title>. <source>J Cell Physiol</source>. (<year>2016</year>) <volume>231</volume>:<fpage>2452</fpage>&#x2013;<lpage>63</lpage>.</mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietkiewicz</surname><given-names>P</given-names></name> <name><surname>Korecka</surname><given-names>K</given-names></name> <name><surname>Salwowska</surname><given-names>N</given-names></name> <name><surname>Kohut</surname><given-names>I</given-names></name> <name><surname>Adhikari</surname><given-names>A</given-names></name> <name><surname>Bowszyc-Dmochowska</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Porokeratoses-a comprehensive review on the genetics and metabolomics, imaging methods and management of common clinical variants</article-title>. <source>Meta</source>. (<year>2023</year>) <volume>13</volume>:1176. doi: <pub-id pub-id-type="doi">10.3390/metabo13121176</pub-id></mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name> <name><surname>Li</surname><given-names>Z</given-names></name> <name><surname>Wang</surname><given-names>J</given-names></name> <name><surname>Ni</surname><given-names>C</given-names></name> <name><surname>Sun</surname><given-names>Z</given-names></name> <name><surname>Wilson</surname><given-names>NJ</given-names></name> <etal/></person-group>. <article-title>Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis</article-title>. <source>J Eur Acad Dermatol Venereol</source>. (<year>2016</year>) <volume>30</volume>:<fpage>1512</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdv.13653</pub-id>, <pub-id pub-id-type="pmid">27422687</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>PQ</given-names></name> <name><surname>Yan</surname><given-names>HM</given-names></name> <name><surname>Zhao</surname><given-names>HJ</given-names></name> <name><surname>Guo</surname><given-names>DY</given-names></name> <name><surname>Jiang</surname><given-names>W</given-names></name></person-group>. <article-title>A novel premature termination mutation in FDPS in a Chinese family with disseminated superficial actinic porokeratosis</article-title>. <source>Br J Dermatol</source>. (<year>2019</year>) <volume>180</volume>:<fpage>1545</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name> <name><surname>Zuo</surname><given-names>N</given-names></name> <name><surname>Yang</surname><given-names>D</given-names></name> <name><surname>Zhang</surname><given-names>D</given-names></name> <name><surname>Feng</surname><given-names>Y</given-names></name> <name><surname>Li</surname><given-names>X</given-names></name></person-group>. <article-title>Novel missense mutations of MVK and FDPS gene in Chinese patients with disseminated superficial actinic porokeratosis</article-title>. <source>Clin Chim Acta</source>. (<year>2021</year>) <volume>523</volume>:<fpage>441</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name> <name><surname>Fu</surname><given-names>X</given-names></name> <name><surname>Wang</surname><given-names>Z</given-names></name> <name><surname>Mi</surname><given-names>Z</given-names></name> <name><surname>Zhang</surname><given-names>H</given-names></name> <name><surname>Yu</surname><given-names>G</given-names></name> <etal/></person-group>. <article-title>Twenty-two novel mutations in a Chinese cohort of 137 patients with porokeratosis were identified using microfluidics (Fluidigm)</article-title>. <source>J Dermatol Sci</source>. (<year>2021</year>) <volume>101</volume>:<fpage>75</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Y</given-names></name> <name><surname>Yan</surname><given-names>L</given-names></name> <name><surname>Feng</surname><given-names>H</given-names></name> <name><surname>Chen</surname><given-names>C</given-names></name> <name><surname>Wang</surname><given-names>S</given-names></name> <name><surname>Luo</surname><given-names>Y</given-names></name> <etal/></person-group>. <article-title>Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis</article-title>. <source>J Dermatol</source>. (<year>2018</year>) <volume>45</volume>:<fpage>862</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1346-8138.14343</pub-id>, <pub-id pub-id-type="pmid">29722423</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atzmony</surname><given-names>L</given-names></name> <name><surname>Lim</surname><given-names>YH</given-names></name> <name><surname>Hamilton</surname><given-names>C</given-names></name> <name><surname>Leventhal</surname><given-names>JS</given-names></name> <name><surname>Wagner</surname><given-names>A</given-names></name> <name><surname>Paller</surname><given-names>AS</given-names></name> <etal/></person-group>. <article-title>Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy</article-title>. <source>J Am Acad Dermatol</source>. (<year>2020</year>) <volume>82</volume>:<fpage>123</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2019.08.043</pub-id>, <pub-id pub-id-type="pmid">31449901</pub-id></mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santa Lucia</surname><given-names>G</given-names></name> <name><surname>Snyder</surname><given-names>A</given-names></name> <name><surname>Lateef</surname><given-names>A</given-names></name> <name><surname>Drohan</surname><given-names>A</given-names></name> <name><surname>Gregoski</surname><given-names>MJ</given-names></name> <name><surname>Barton</surname><given-names>V</given-names></name> <etal/></person-group>. <article-title>Safety and efficacy of topical lovastatin plus cholesterol cream vs topical lovastatin cream alone for the treatment of disseminated superficial actinic porokeratosis: a randomized clinical trial</article-title>. <source>JAMA Dermatol</source>. (<year>2023</year>) <volume>159</volume>:<fpage>488</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0008">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3197787/overview">Pawe&#x0142; Pietkiewicz</ext-link>, Unitelematica Leonardo da Vinci, Switzerland</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0009">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1275854/overview">Cristian Navarrete-Dechent</ext-link>, Pontificia Universidad Cat&#x00F3;lica de Chile, Chile</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3307169/overview">Vishal Gupta</ext-link>, All India Institute of Medical Sciences, India</p>
</fn>
</fn-group>
<fn-group>
<fn id="fn0001"><label>1</label><p><ext-link xlink:href="https://genome.ucsc.edu" ext-link-type="uri">https://genome.ucsc.edu</ext-link></p>
</fn>
<fn id="fn0002"><label>2</label><p><ext-link xlink:href="http://zhanglab.ccmb.med.umich.edu/I-TASSER/" ext-link-type="uri">http://zhanglab.ccmb.med.umich.edu/I-TASSER/</ext-link></p>
</fn>
<fn id="fn0003"><label>3</label><p><ext-link xlink:href="http://provean.jcvi.org/index.php" ext-link-type="uri">http://provean.jcvi.org/index.php</ext-link></p>
</fn>
<fn id="fn0004"><label>4</label><p><ext-link xlink:href="http://genetics.bwh.harvard.edu/pph2" ext-link-type="uri">http://genetics.bwh.harvard.edu/pph2</ext-link></p>
</fn>
<fn id="fn0005"><label>5</label><p><ext-link xlink:href="http://sift.bii.astar.edu.sg" ext-link-type="uri">http://sift.bii.astar.edu.sg</ext-link></p>
</fn>
<fn id="fn0006"><label>6</label><p><ext-link xlink:href="http://www.mutationtaster.org" ext-link-type="uri">http://www.mutationtaster.org</ext-link></p>
</fn>
</fn-group>
</back>
</article>